Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.47 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.47 |
| ▸ | FABP2 | P12104 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096264 | 0.85 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8084321 | 0.84 | POLB (0.54) | POLBNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL12302098 | 0.83 | ALDH1A1 (0.55) | POLBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24534686 | 0.83 | HDAC1 (0.60) | POLBNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12024323 | 0.83 | POLB (0.53) | POLBNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL2949568 | 0.82 | POLB (0.61) | POLBNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL343830 | 0.82 | POLB (0.65) | POLBNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3752476 | 0.82 | POLB (0.53) | POLBNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL1742088 | 0.81 | EGLN1 (0.50) | POLBNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL22987120 | 0.81 | MAPT (0.49) | POLBNPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111196772-B | Aroylamino isobutyryl derivative and application thereof | 沈阳化工研究院有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-111196772-A | Aroylamino isobutyryl derivative and application thereof | 沈阳化工研究院有限公司 | 2020-05-26 | — | — | CN | disclosed |
| WO-2017115329-A1 | C-3 NOVEL TRITERPENONE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-07-06 | — | — | WO | disclosed |
| EP-2212334-B1 | PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-7838673-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| EP-2212334-A1 | PROTEASOME INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009051581-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099132-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099132-A1 | Proteasome inhibitors | PSMB5, PSMG3, PSMB1 | POLB 836/4885NPC1 1095/4885RAB9A 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.